Compound A delays autoimmune diabetes in NOD mice

BARCALA TABARROZI, AE; CASTRO, CN; ANTUNICA NOGUEROL, M; LIBERMAN, AC; DE BOSSCHER, K; HAEGEMAN, G; ARZT, E; PERONE, MJ

Capital Federal

Workshop; Frontiers in BioScience- Joint Symposium of the Max Planck Society and the Ministry of Science, Technology and Innovation.; 2012

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease due to self destruction of insulin-secreting beta-cells by immune cells. Compound A (CpdA) is a glucocorticoid receptor (GR) dissociative ligand derived from Salsola tuberculatiformis Botschantzev. CpdA interferes with NFkB activity without inducing glucocorticoid response elements-driven genes. Moreover CpdA ameliorates symptoms in both rheumatoid arthritis and multiple sclerosis models modulating the autoimmune response. Herein, we present the therapeutic potential of CpdA in T1DM by using an adoptive transfer model of this disease